Freund's Adjuvant

Freund's adjuvant is a solution of antigen emulsified in mineral oil and used as an immunopotentiator (booster). The complete form, Freund's Complete Adjuvant (CFA or FCA) is composed of inactivated and dried mycobacteria (usually M. tuberculosis), whereas the incomplete form (IFA or FIA) lacks the mycobacterial components (hence just the water in oil emulsion). It is named after Jules T. Freund.

Freund's complete adjuvant is effective in stimulating cell-mediated immunity and leads to potentiation of T helper cells that leads to the production of certain immunoglobulins and effector T cells. Its use in humans is forbidden by regulatory authorities, due to its toxicity. Even for animal research there are currently guidelines associated with its use, due to its painful reaction and potential for tissue damage. Injections of CFA should be subcutaneous or intraperitoneal, because intradermal injections may cause skin ulceration and necrosis; intramuscular injections may lead to temporary or permanent muscle lesion, and intravenous injections may produce pulmonary lipid embolism.^{[citation needed]}

When administered to diabetes prone NOD mice Freund's complete adjuvant (FCA) prevented juvenile-onset diabetes. When combined with spleen cells FCA was said to have reversed diabetes. In 2006 these claims were confirmed that even without spleen cells CFA can restore insulin producing beta cells in pancreas of NOD mice. Although newspapers have described the 2006 findings as confirming the earlier experiments,. A report from NIH was released on November 23, 2006 in Science confirming the participation of spleen cells in reversing end-stage diabetes.

...
Wikipedia